Skip to main content
. 2018 Nov 25;85(2):347–355. doi: 10.1111/bcp.13794

Figure 2.

Figure 2

Mean changes in BCVA (ETDRS letters) (A) and CRT (B) from baseline in 51 patients with neovascular age‐related macular degeneration following treatment with regorafenib 30 mg ml–1 three times daily for 12 weeks. BCVA, best‐corrected visual acuity; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; SE, standard error